Research programme: stem cell therapeutics - Cellular Dynamics International/National Eye Institute

Drug Profile

Research programme: stem cell therapeutics - Cellular Dynamics International/National Eye Institute

Alternative Names: Retinal disease therapeutics - Cellular Dynamics International/National Eye Institute

Latest Information Update: 27 Sep 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Eye Institute
  • Developer Cellular Dynamics International; National Eye Institute
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Age-related macular degeneration

Most Recent Events

  • 22 Jun 2016 Cellular Dynamics International establishes CRADA with the National Eye Institute for the development of Stem cell therapeutics in Ocular disorders
  • 10 Nov 2014 Preclinical trials in Age-related macular degeneration in USA (Intraocular)
  • 27 Oct 2014 National Eye Institute awards a $US1.2 million contract to Cellular Dynamics International to manufacture induced pluripotent stem cells
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top